title: Treatment of acute hepatitis C-how to explain the differences?
authors.forename: Heiner
authors.initials: H
authors.lastname: Wedemeyer
authors.forename: Markus
authors.initials: M
authors.lastname: Cornberg
authors.forename: Johannes
authors.initials: J
authors.lastname: Wiegand
authors.forename: Elmar
authors.initials: E
authors.lastname: Jäckel
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D004337:Drug Carriers; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a